AD, atopic dermatitis.
References
MAT-GB-2104841(v2.0) | Date of preparation: February 2022
Sanofi and Regeneron are collaborating in a global development programme and commercialisation for Dupixent.
Copyright © 2022 Aventis Pharma Limited. All rights reserved.
Great Britain Summary of Product Characteristics Northern and Republic of Ireland Summary of Product Characteristics
Terms of Use | Privacy Policy | Cookies Policy | Site Map | Contact Us
This link takes you to a third party website. Sanofi Genzyme has no control over the content of the website you are about to access. The terms of usage of the third party website will differ from that of the www.dupixent.co.uk. It is recommended that you carefully read the legal notice, cookies and privacy policy of third party websites before accessing these sites.
By continuing you are acknowledging that you have read this notice.
MAT-IE-2101043(v3.0) | Date of preparation: October 2021
DUPIXENT is now recommended for specific use in England and Wales1
by NICE Technology Appraisal Guidance (TA751) as an add-on option for treating severe asthma despite maintenance therapy in patients who meet the following criteria:
✔ For adults and adolescents 12 and older with Type 2 inflammation characterised by raised eosinophils (EOS) (≥150 cells/μL) and raised fraction of exhaled nitricoxide (FeNO) (≥25 ppb)
✔ Who are inadequately controlled with high-dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment
✔ With ≥4 annual exacerbations
Reference: 1. NICE guidance. Available at: https://www.nice.org.uk/guidance/TA751/.
Date accessed: December 2021.
MAT-GB-2104922(v2.0) | Date of preparation: December 2021
